BioInvent, Immusol form collaboration to develop antibody for AMD

By Lisa Kerner

Erie, Pa., April 3 - BioInvent International AB and Immusol, Inc. will collaborate on the development of a fully human n-CoDeR antibody for the treatment of age-related macular degeneration (AMD) and other ophthalmic disorders.

Macular degeneration, the most common cause of vision loss in people over age 60, is characterized by abnormal vessel growth in the eye.

Under the terms of the collaboration, the two companies will share costs and revenues associated with product development and commercialization, according to a company news release.

"We are happy to work with BioInvent to leverage BioInvent's antibody expertise in an important disease area," Immusol chief scientific officer and executive vice president Flossie Wong-Staal said in the release.

"By developing antibodies against a non-VEGF target with proven preclinical efficacy, we hope to tackle wet AMD from a different angle."

San Diego-based Immusol offers expertise in ophthalmology and intellectual property rights covering the use of antagonists against a biological target playing a role in AMD.

BioInvent develops therapeutic antibodies against diseases where there is a significant unmet medical need. The company is located in Lund, Sweden.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.